Ghatkopar (East), Mumbai)
Home >Dermatology > Alopecia Areata
Alopecia Areata
Alopecia areata arrives without warning. A coin-sized bald patch discovered in the mirror, a handful of hair on the pillow, a child's teacher noticing a smooth bare circle on the scalp. Unlike androgenetic alopecia, alopecia areata is not about follicle miniaturisation the follicles are intact and alive, but the immune system has declared them foreign and mounted an attack. It is autoimmune hair loss driven by T cells surrounding the hair follicle and shutting down its cycle. The hair can regrow fully, and spontaneously in many cases. But in severe or extensive disease, it will not grow back without treatment.
At Shree Hospitals, our alopecia areata treatment in Mumbai matches the treatment intensity to the disease extent because a single small patch requires a different approach than totalis or universalis.
(24×7 Emergency Care)
Our Approach
(24×7 Emergency Care)
Our Approach in Managing Alopecia Areata
Shree Hospitals — Life-saving care
The first conversation in alopecia areata management is about prognosis. Single patches in an otherwise healthy adult carry an 80% spontaneous remission rate. Extensive scalp involvement, nail changes, alopecia totalis, onset in childhood, and atopy are all poor prognostic indicators. Our alopecia areata specialist dermatologist team in Mumbai, India stratifies every patient by prognostic risk before deciding on treatment intensity because aggressive immunosuppression in a self-limiting single patch is over-treatment, and watchful waiting in extensive alopecia totalis is under-treatment.
- Diagnosis & Extent Classification
- Clinical diagnosis smooth, well-defined, circular or oval patches of complete hair loss; exclamation mark hairs (tapering at the base) at patch margins confirm activity
- Trichoscopy yellow dots (follicular infundibula), black dots (cadaverised hair), broken hairs, and exclamation mark hairs characterise the trichoscopic pattern
- Severity Assessment of Alopecia Tool (SALT score) — percentage of scalp hair loss; used for clinical trials and treatment response monitoring
- Nail examination — pitting, trachyonychia, longitudinal ridging — nail involvement in 10–20% of patients; associated with more extensive disease
- Ophiasis pattern — band-like loss at the peripheral scalp (temporal, occipital) — poor prognostic variant
- Associated autoimmune conditions: thyroid disease (most common), vitiligo, type 1 diabetes screening at diagnosis
- Treatment for Limited Patchy Alopecia Areata
- Intralesional corticosteroid injections Triamcinolone acetonide 2.5–5mg/mL injected at 1cm intervals within patches; the most effective first-line treatment for limited patchy AA; repeated every 4–8 weeks
- Topical corticosteroids less effective than intralesional; useful for children where injections are not tolerated; high-potency Clobetasol under occlusion
- Topical Minoxidil adjunct to stimulate any regrowth that follows immune suppression; enhances regrowth in alopecia areata
- Contact immunotherapy (DPCP/SADBE) topical sensitiser applied to induce contact dermatitis that shifts the immune response away from the follicle; effective in extensive or refractory patchy AA; produces regrowth in alopecia areata in 40–60% of patients
- Treatment for Extensive, Totalis & Universalis
Extensive autoimmune hair loss requires systemic or biologic intervention.
- Oral corticosteroids pulse Dexamethasone or daily Prednisolone; rapid but temporary response; significant relapse on stopping; limited to bridging therapy or acute extensive flares
- Methotrexate weekly oral or SC injection; used in extensive AA or when combined with low-dose systemic steroids; response rate 30–50%; teratogenic
- Cyclosporine effective; limited by renal and BP toxicity; used for severe rapidly progressive AA
- JAK inhibitor for alopecia areata the biggest advance in AA treatment in decades
- Baricitinib (Olumiant) FDA-approved for severe AA; 4mg daily; SALT-50 response (≥50% scalp coverage) in 38% at week 36 (BRAVE-AA trial)
- Ritlecitinib FDA-approved 2023; daily oral; effective in adolescents from age 12; strong safety data
- Upadacitinib off-label; impressive response rates in severe AA; widely used in clinical practice
- Deuruxolitinib in clinical trials; early results showing significant hair regrowth including in totalis/universalis
- Contact Immunotherapy — DPCP
Diphenylcyclopropenone (DPCP) is the most effective topical treatment for extensive patchy alopecia areata.
- Sensitisation session followed by weekly escalating concentration applications to the scalp
- Controlled allergic contact dermatitis is induced the immune shift away from follicular attack allows regrowth
- Requires 3–6 months before response is seen
- Effective in patients with >50% scalp involvement where intralesional injections are impractical
- Psychological Support & Quality of Life
Alopecia areata particularly totalis and universalis has a profound psychological impact that the medical team cannot ignore.
- Anxiety and depression rates significantly elevated in alopecia areata compared to the general population
- Peer support groups and psychologist referral as part of the treatment plan
- Wig prescription and hair prosthesis guidance for patients with totalis or universalis
- Child-specific considerations school support letters, social stigma management, age-appropriate treatment selection
- Monitoring & Relapse Management
- Monthly trichoscopy in active disease tracks yellow dot count (stable follicle reserve), regrowth pattern, and activity markers
- Thyroid function annually the most common autoimmune comorbidity
- Relapse planning patients with prior extensive AA are counselled on early re-treatment triggers; JAK inhibitors may need to be continued rather than stopped on achieving response
Happy Patients & Their Case Stories
She presented with three patches of patchy alopecia areata — SALT score 18%. No nail involvement, no personal autoimmune history. Intralesional Triamcinolone was administered at 6-weekly intervals. All three patches showed complete regrowth in alopecia areata at 4 months. She was followed up at 6 months and 12 months without recurrence and discharged from active follow-up.
Mrs. Priya R.
He had developed alopecia totalis over 8 months — no scalp hair, eyebrow loss, and early eyelash thinning. SALT score was 100. Previous oral steroid pulses had produced temporary regrowth followed by relapse. He was started on Ritlecitinib 50mg daily at Shree Hospitals. At 6 months, SALT score had improved to 42 (58% regrowth). At 12 months, SALT was 15 near-complete regrowth. He continues on maintenance Ritlecitinib with monthly monitoring
Mr. Rohan S.
How to Identify Alopecia Areata ?
Alopecia areata has a distinctive appearance that allows clinical diagnosis in most cases without investigation.
Features pointing to alopecia areata rather than other hair loss types:
- Round or oval patches of complete, smooth hair loss no scaling, no redness, no skin change within the patch
- Exclamation mark hairs short broken hairs that taper at the base visible at the edge of active patches
- Multiple patches simultaneously or appearing in rapid succession
- Loss occurring on any hair-bearing body site scalp, beard, eyebrows, eyelashes, body not just scalp
- Onset at any age unlike androgenetic alopecia, alopecia areata affects children as commonly as adults
- Nail changes fine pitting in a geometric grid pattern, roughness, or complete nail dystrophy (trachyonychia)
- Rapid onset patches appear over days; the sudden temporal profile distinguishes it from androgenetic alopecia
The most important prognostic information is obtained at the first visit: extent of involvement, pattern (patchy vs. ophiasis vs. totalis), nail involvement, age of onset, and duration. This information determines whether a patient is likely to recover spontaneously or whether systemic or biologic intervention with a JAK inhibitor for alopecia areata is indicated early. Seek alopecia areata treatment in Mumbai from a trichology team that stratifies prognosis before treatment not one that simply injects steroids into every patch without regard for the clinical picture.
Important FAQs:Alopecia Areata
Will alopecia areata grow back on its own
In limited patchy disease (1–3 patches, <25% scalp involvement), spontaneous regrowth within 12 months occurs in approximately 80% of cases. Extensive disease, ophiasis, totalis, and universalis have much lower spontaneous recovery rates.
Can stress cause alopecia areata?
Psychological stress is a recognised trigger for onset and relapse of alopecia areata in genetically predisposed individuals. It is not the sole cause, but stress management is part of comprehensive care.
Is alopecia areata contagious?
Not at all. It is an autoimmune condition — entirely internal to the patient's own immune system. It cannot be transmitted through any form of contact.
How long does JAK inhibitor therapy take to produce regrowth?
Baricitinib and Ritlecitinib typically produce visible regrowth within 8–12 weeks. Significant cosmetic improvement (SALT-50) is achieved in 35–45% of patients at 36 weeks. Treatment must be continued to maintain response.
Does alopecia areata affect children differently?
Children have similar presentations but higher rates of nail involvement and extensive disease compared to adults. JAK inhibitors — particularly Ritlecitinib are now approved from age 12 for severe cases.
Treatments For Alopecia Areata At Shree Hospitals
Treatments for Alopecia Areata at Shree Hospitals.Comprehensive patchy hair loss diagnosis and treatment in Mumbai from intralesional corticosteroids to JAK inhibitor biologic therapy.
Top Alopecia & Hair Disorder Specialists in Mumbai
Dr. Snehal Thank
Pioneer Pediatric Physiotherapist & Neuro-Developmental
Dr. Yogesh Kalyanpad
Dermatology, Cosmetology and Hair Transplant
Every doctor and specialist at Shree Hospitals is board-certified and brings an average of 15 or more years of clinical experience in their area of subspecialty.
For Appointment/Query
1800-268-4000
Tele consultation/2nd Opinion
Schedule Consultation
News & Updates
Shree Hospitals is the first to perform robotic endo surgery.
Shree Hospitals Introduces Advanced Robotic Surgery for Better Patient Care
Shree Hospitals Expands Advanced Surgical Care With Latest Medical Technology
